The aim of this study was to assess the burden of PE, in terms of mortality and health-related quality of life (HrQoL), as a function of patient characteristics, across Europe. MethOds: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries (France, Italy, Spain, UK, and DACH (Germany, Switzerland and Austria)). Venous thromboembolism (VTE) patients, following an acute event (index event), were recruited and followed at 1, 3, 6 and 12 months. The study sample was 1399 patients with PE. Subgroup analysis by country and with active cancer were conducted. The association between patient characteristics and mortality/HrQoL (EQ-5D-5L) were examined using a regression approach with the total sample. Results: Average mortality rate at 12 months was 8.1%, varying between observed regions (1.4% in DACH to 16.8% in Italy), and substantially differed between patients with active cancer and those without (42.7% vs. 4.7%). Cancer was one of the most significant predictors for mortality, other predictors include age, BMI, more than 5 days bed rest, vascular disease, previous AF, smoking history and symptoms of palpitations. EQ-5D-5L index score at baseline (right after the index event) was 0.712 (SD: 0.265), and gradually improved to 0.835 (0.212) at 12 months. When scoring non-survivors at zero, average quality of life decreased to 0.743 at 12 months. Similarly, the index scores varied between observed countries and cancer subgroups. Active cancer, previous stroke and provoked VTE are amongst other significant factors for predicting index scores. cOnclusiOns: PE is associated with a substantial burden of illness -increasing mortality rate and decreasing HrQoL. Country variation exist and active cancer has a significantly large impact on PE burden.

No abstract

paclitaxel or docetaxel, after adjuvant chemotherapy. For mBC, associations with docetaxel or paclitaxel were considered for first line and monotherapy for second. A survey was performed with 28 HMOs to map fees and sources used for reimbursement of drugs, materials and procedures. Resource use estimates were performed by a multidisciplinary team. Direct medical costs were included; drugs and material prices were obtained from published sources and fees from survey results. Time horizon was 5 years and market share considered the uptake of subcutaneous trastuzumab starting with 20% in the first year, increasing to 100% in the fifth year. A deterministic sensitivity analysis was conducted to analyze model robustness. RESULTS: In 5 years, 31,589 breast cancer patients were estimated for the private healthcare system, 284 patients for big, 30 patients for medium, and 6 patients for small HMOs. The progressive uptake of subcutaneous trastuzumab, compared with intravenous, can save up to 948,2 mBRL, 14,3 mBRL, 1,5 mBRL and 0,2 mBRL, respectively. Materials and support procedures along with medical fees were the most sensitive parameters. CONCLUSIONS: Compared with the intravenous administration, subcutaneous trastuzumab can save up to 948,2 mBRL costs on breast cancer treatment in the Private Healthcare System.

The use of bortezomib SQ instead of IV could provide access to a highly efficacious therapy while conferring savings to Mexican public payers. Given non-inferior efficacy, migration from IV to SQ bortezomib results in improved tolerability and reduced administration requirements without reducing clinical benefits from treatment.

the respective countries were elicited from local experts and clinical guidelines in addition to 1L> 2L BEV sequences obtained from the ML18147 trial. Results: When 1L> 2L BEV replaces sequences which include 1L anti-EGFR regimens, it results in an average potential cost reduction of 796